Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Hyloris Developmentsen Sa (HYL)

Brussels
Currency in EUR
Disclaimer
11.70
-0.15(-1.27%)
Closed
HYL Scorecard
Fair Value
Unlock Value
Day's Range
11.7011.90
52 wk Range
10.6014.10
Prev. Close
11.85
Open
11.9
Day's Range
11.7-11.9
52 wk Range
10.6-14.1
Volume
5,657
Average Vol. (3m)
11,199
1-Year Change
-8.59%
Shares Outstanding
28,000,374
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell

People Also Watch

2.535
DECB
+0.20%
18.00
EKOP
+0.28%
12.86
IBAB
-0.77%
9.60
NYXH
+2.78%
149.60
DEME
+2.19%
How do you feel today about HYL?
Vote to see community's results!
or

Hyloris Developmentsen Sa Company Profile

Hyloris Pharmaceuticals SA is a Belgium-based bio-pharmaceutical company. The Company focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. It has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. It also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.

Employees
21
Market
Belgium
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.